This poster was presented at the 30th annual Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.
Objective: To describe patients with major depressive disorder (MDD) switching to vortioxetine, and examine treatment patterns and healthcare resource use and costs before and after switching from another antidepressant treatment.
Methods: US claims data (2010-2015) from Integrated DataVerse (Symphony Health) of adults (≥18 years) with ≥2 MDD diagnosis records switching to vortioxetine were reviewed. The index date was the switch date (prescription fill) from another antidepressant to vortioxetine. In a mirror study, healthcare resource utilization, costs, and treatment persistence and adherence were compared for the 6-month pre- and post-index periods.
Results: Among patients switching to vortioxetine (n=14,692), 74.5% were women; mean±SD age was 46.9±14.6 years. Before switching, patients had a mean±SD Charlson-Quan Comorbidity Index score of 0.6±1.25. The most common comorbid diagnoses were anxiety disorders (36.4%) and substance related disorders (12.6%); 48.2% of patients used 1 antidepressant, with selective serotonin reuptake inhibitors most commonly prescribed (50.6%). Comparing the 6-month pre- vs post-index periods, mean±SD values were 5.3±7.2 vs 5.2±7.2 for all-cause healthcare visits, $7,548±16,939 vs $9,087±17,508 for total healthcare costs, $1,753±3,302 vs $3,241±4,121 for pharmacy costs, and $5,794±16,384 vs $5,846±16,758 for medical services costs. Persistence (mean±SD days to discontinuation) was 113.4±61.7 vs 135.8±50.5 and adherence (mean±SD medication possession ratios) was 90.6±13.5 vs 91.1±12.2 for the pre- vs post-index periods.
Conclusions: Improved treatment persistence and similar adherence were observed after switching to vortioxetine. Increased total healthcare costs post-switch were primarily due to higher pharmacy costs; in contrast, medical services costs remained relatively steady.